UBriGene and Cellinfinity BIO Collaborate to Accelerate in Vivo CAR-T Therapies

Why It Matters

By combining cutting‑edge vector manufacturing with novel CAR designs, the collaboration could lower CAR‑T production costs and accelerate market entry for therapies that address unmet oncology and autoimmune needs.

Key Takeaways

• uBriGene supplies GMP lentiviral vectors via LVV Turbo platform.
• LVV Turbo achieves 80% purification recovery, 5× transduction titres.
• CIB‑301 targets multiple solid tumor antigens with human scFv.
• CIB‑350 uses bispecific CAR for B‑cell diseases and autoimmunity.
• Partnership aims to lower CAR‑T production costs and expand access.

Pulse Analysis

In‑vivo CAR‑T therapy is emerging as a potential game‑changer for oncology and immunology, promising off‑the‑shelf solutions that bypass the logistical hurdles of ex‑vivo cell manufacturing. The market has been hampered by high production costs and complex supply chains, limiting patient access despite strong clinical data. uBriGene’s collaboration with Cellinfinity BIO directly tackles these barriers by marrying a robust lentiviral vector platform with innovative CAR constructs, positioning both companies to capture a growing share of the cell‑therapy market.

The LVV Turbo platform distinguishes itself through a fully closed downstream purification process, an ultra‑T enhancer, and a high‑productivity 293TH suspension cell line. These technologies collectively deliver up to 80% vector recovery and a five‑fold boost in transduction titres, translating into lower cost‑of‑goods per dose. Such efficiencies are critical as payers scrutinize the economics of CAR‑T, and they enable scalable GMP manufacturing that can meet rising demand without sacrificing quality or safety.

Cellinfinity’s pipeline adds strategic depth to the partnership. CIB‑301 employs a fully human single‑chain variable fragment to target antigens across colorectal, endometrial, non‑small cell lung, ovarian, and renal cancers, aiming for high specificity and reduced off‑target toxicity. Meanwhile, CIB‑350’s bispecific CAR design addresses both autoimmune disorders and B‑cell malignancies by simultaneously engaging two antigens, a novel approach that could improve response durability. Together, these programs expand the therapeutic horizon beyond hematologic indications, offering investors and clinicians a broader portfolio of next‑generation CAR‑T candidates poised for clinical advancement.